The immunopotentiator CVC1302 enhances immune efficacy and protective ability of foot-and-mouth disease virus vaccine in pigs.

Abstract:

:The immunological enhancement characteristics of the immunopotentiator CVC1302 were evaluated for foot-and-mouth disease virus (FMDV) inactivated vaccine in pigs. Eight-week-old piglets were vaccinated with the foot-and-mouth disease (FMD) vaccine alone (FMD-vaccine group) or with the addition of CVC1302 (FMD-CVC1302 group), and the serum liquid phase blocking ELISA (LPB-ELISA) antibody titers, IgG1 and IgG2 levels, and the levels of four cytokines secreted by peripheral blood lymphocytes were measured at 28 days post vaccination (dpv). In the FMD-CVC1302 group, the LPB-ELISA antibody titers, IgG1, and IgG2 titers, and IL-2, IL-4, IL-6, and IFN-γ levels at 28 dpv were significantly higher than those in the FMD-vaccine group. The FMD-CVC1302 group had long-lasting antibody titers (>7.8 log2), lasting for at least 6 months. In addition, piglets were vaccinated with or without addition of CVC1302 to the FMD vaccine at three different doses (1, 1/3, and 1/9 of the standard vaccine dose) and the serum LPB-ELISA antibody and serum neutralizing (SN) antibody titers were detected at 28 dpv. Then all pigs were challenged with virulent FMDV for PD50 value, and the levels of FMDV-specific RNA copies for the two full-dose groups at 3 and 10 days post challenge (dpc) were measured. The LPB-ELISA and SN antibody titers for the three doses in the FMD-CVC1302 groups were significantly higher than those in the FMD-vaccine groups at the same doses (p < 0.05). Post-virus challenge, the FMDV-specific RNA copy number in the FMD-CVC1302 group was lower than that in the FMD-vaccine group at 3 and 10 dpc. The PD50 value was 15.85 for the FMD-CVC1302 group, which was obviously higher than that for the FMD-vaccine group (10.96), and in the 1/9-dose of FMD-vaccine group only 3/5 pigs were protected. These results indicate that CVC1302 can enhance the immune efficacy and protective ability of the FMD vaccine in pigs.

journal_name

Vaccine

journal_title

Vaccine

authors

Chen J,Yu X,Zheng Q,Hou L,Du L,Zhang Y,Qiao X,Hou J,Huang K

doi

10.1016/j.vaccine.2018.11.012

subject

Has Abstract

pub_date

2018-12-18 00:00:00

pages

7929-7935

issue

52

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(18)31523-8

journal_volume

36

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Complications of influenza and benefits of vaccination.

    abstract::Uncertainty regarding the benefits of influenza vaccination may contribute to the underutilization of this vaccine. We have conducted serial cohort studies using the administrative data bases of a Twin Cities based managed care organization to assess the impact of disease and benefits of vaccination among the elderly....

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究

    doi:10.1016/s0264-410x(99)00105-x

    authors: Nichol KL

    更新日期:1999-07-30 00:00:00

  • Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.

    abstract::Toxoplasma gondii is an intracellular parasite that causes severe neurologic and ocular disease in immune-compromised and congenitally infected individuals. There is no vaccine protective against human toxoplasmosis. Herein, immunization of L(d) mice with HF10 (HPGSVNEFDF) with palmitic acid moieties or a monophosphor...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.03.028

    authors: Tan TG,Mui E,Cong H,Witola WH,Montpetit A,Muench SP,Sidney J,Alexander J,Sette A,Grigg ME,Maewal A,McLeod R

    更新日期:2010-05-21 00:00:00

  • Impact of a 2-dose voluntary vaccination strategy on varicella epidemiology in Beijing, 2011-2017.

    abstract:BACKGROUND:One-dose voluntary varicella vaccination for children was introduced in Beijing since 1998. In Oct 2012, a second dose varicella vaccine (VarV) was recommended to further decrease varicella disease and the outbreaks. We describe the impact of the 2-dose voluntary vaccination strategy on varicella epidemiolog...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.01.087

    authors: Suo L,Lu L,Zhao D,Pang X

    更新日期:2020-04-29 00:00:00

  • Antibodies against cell surface antigens as very potent immunological adjuvants.

    abstract::We describe here two very potent adjuvant systems which are thought to work directly on antigen specific lymphocytes, thus by-passing the normal route for adjuvants, which is to activate antigen presenting cells (APCs) inducing release of inflammatory cytokines with resultant side effects of local and systemic reactog...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.01.105

    authors: Barr T,Carlring J,Hatzifoti C,Heath AW

    更新日期:2006-04-12 00:00:00

  • Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.

    abstract:BACKGROUND:Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV-1 related morbidity and mortality globally transforming HIV into a controllable condition. HAART has a number of limitations though, including limited access in resource constrained countries, which have driven the searc...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2012.04.007

    authors: Vardas E,Stanescu I,Leinonen M,Ellefsen K,Pantaleo G,Valtavaara M,Ustav M,Reijonen K

    更新日期:2012-06-08 00:00:00

  • Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine.

    abstract::Ten adult volunteers, with low prevaccination levels of serum IgG antibodies against meningococcal antigens (< 1 microg ml(-1)), received three doses of the Norwegian group B meningococcal outer membrane vesicle (OMV) vaccine intramuscularly at weeks 0, 6 and 46. Anti-OMV IgG subclass responses were measured and compa...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(98)00259-x

    authors: Naess LM,Aarvak T,Aase A,Oftung F,Høiby EA,Sandin R,Michaelsen TE

    更新日期:1999-02-26 00:00:00

  • Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose.

    abstract::Longitudinal serum samples were collected from 542 children that had participated in a Swedish pertussis vaccine trial 1992-1995 [Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Me...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2005.06.009

    authors: Hallander HO,Gustafsson L,Ljungman M,Storsaeter J

    更新日期:2005-11-16 00:00:00

  • Attitudes towards influenza vaccination of multi-nationality health-care workers in Saudi Arabia.

    abstract:BACKGROUND:The compliance with influenza vaccination among health-care workers (HCWs) is known to be low. A multi-nationality survey to explore the reasons for such poor compliance has not been studied in depth. MATERIALS AND METHODS:An epidemiologic survey to evaluate the compliance rates with influenza vaccination a...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.06.108

    authors: Al-Tawfiq JA,Antony A,Abed MS

    更新日期:2009-09-04 00:00:00

  • Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration.

    abstract::In the United States, co-administration of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine and tetravalent meningococcal conjugate vaccine (MCV4) is recommended in adolescents. In this clinical study, 1341 adolescents received Tdap (Boostrix® GlaxoSmithKline) and MCV4 (Menactra®, Sanof...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2010.11.057

    authors: Weston WM,Friedland LR,Wu X,Howe B

    更新日期:2011-01-29 00:00:00

  • Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type B conjugate vaccines given for primary immunisation by separate or mixed injection.

    abstract::The safety and immunogenicity of two conjugate Haemophilus influenzae type B (Hib) vaccines administered either mixed with, or in separate limbs to, a whole-cell DTP vaccine, was compared in infants vaccinated at 2, 3 and 4 months of age. Antibody titres to purified polyribosylribitol phosphate, diphtheria, and to per...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/0264-410x(95)00091-e

    authors: Begg NT,Miller E,Fairley CK,Chapel HM,Griffiths H,Waight PA,Ashworth LA

    更新日期:1995-11-01 00:00:00

  • Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.

    abstract::Previous studies with the malaria vaccine RTS,S/AS02(A) in young children in a malaria endemic area of Mozambique have shown it to have a promising safety profile and to reduce the risk of Plasmodium falciparum infection and disease. In this study, we assessed the antibody responses to the P. falciparum and hepatitis ...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2011.03.041

    authors: Aide P,Dobaño C,Sacarlal J,Aponte JJ,Mandomando I,Guinovart C,Bassat Q,Renom M,Puyol L,Macete E,Herreros E,Leach A,Dubois MC,Demoitie MA,Lievens M,Vekemans J,Loucq C,Ballou WR,Cohen J,Alonso PL

    更新日期:2011-08-11 00:00:00

  • Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada.

    abstract:BACKGROUND:British Columbia (BC) introduced a school-based HPV vaccine program in September 2008. As part of the HPV vaccine program evaluation, we determined the type-specific HPV prevalence in a population-based sample of women presenting for routine cervical cancer screening in the province. METHODS:From June 2010 ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.09.085

    authors: Ogilvie GS,Cook DA,Taylor DL,Rank C,Kan L,Yu A,Mei W,van Niekerk DJ,Coldman AJ,Krajden M

    更新日期:2013-02-04 00:00:00

  • Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.

    abstract::Two double-blind randomised controlled studies (phase I and I/II) were performed to assess for the first time the safety and immunogenicity of a recombinant subunit gp350 Epstein-Barr virus (EBV) vaccine in 148 healthy adult volunteers. All candidate vaccine formulations had a good safety profile and were well tolerat...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2007.04.008

    authors: Moutschen M,Léonard P,Sokal EM,Smets F,Haumont M,Mazzu P,Bollen A,Denamur F,Peeters P,Dubin G,Denis M

    更新日期:2007-06-11 00:00:00

  • A combination vaccine confers full protection against co-infections with influenza, herpes simplex and respiratory syncytial viruses.

    abstract::Combined/composite vaccines should be useful in reducing the number of vaccinations and provide more flexibility in confronting biological warfare scenarios. We tested the effectiveness of a composite genetic vaccine designed from previously known protective antigens directed against influenza A virus (INF-A), herpes ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00352-8

    authors: Talaat AM,Lyons R,Johnston SA

    更新日期:2001-11-12 00:00:00

  • Adjuvant activity of fish type I interferon shown in a virus DNA vaccination model.

    abstract::There is a need for more efficient vaccines to combat viral diseases of Atlantic salmon and other farmed fish. DNA vaccines are highly effective against salmonid rhabdoviruses, but have shown less effect against other viruses. In the present work we have studied if type I IFNs might be used as adjuvants in fish DNA va...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.03.093

    authors: Chang CJ,Sun B,Robertsen B

    更新日期:2015-05-15 00:00:00

  • Correlation of haemagglutinin-neuraminidase and fusion protein content with protective antibody response after immunisation with inactivated Newcastle disease vaccines.

    abstract::The correlation between the antigen content of inactivated Newcastle disease (ND) oil emulsion-vaccines and the serological response after immunisation was studied. The haemagglutinin-neuraminidase (HN) and fusion (F) proteins of Newcastle disease virus (NDV) were quantified in 33 inactivated oil-adjuvanted ND vaccine...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(03)00249-4

    authors: Maas RA,Komen M,van Diepen M,Oei HL,Claassen IJ

    更新日期:2003-07-04 00:00:00

  • Protection against influenza virus infection by nasal vaccination in advance of sublethal irradiation.

    abstract::The effect of sublethal gamma-ray irradiation on the protection conferred by a nasal influenza vaccine was investigated in BALB/c mice. A radiation dose of 7 Gy was selected as the sublethal dose as this caused exacerbation of the influenza but was not lethal in the mouse model. Mice were irradiated 7 days before, on ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00553-8

    authors: Hasegawa H,Kadowaki S,Takahashi H,Iwasaki T,Tamura S,Kurata T

    更新日期:2000-05-22 00:00:00

  • Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL-12, dose, and route.

    abstract::Improving the ability of DNA-based vaccines to induce potent Type1/Th1 responses against intracellular pathogens in large outbred species is essential. Rhodoccocus equi and equine infectious anemia virus (EIAV) are two naturally occurring equine pathogens that also serve as important large animal models of neonatal im...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.07.055

    authors: Mealey RH,Stone DM,Hines MT,Alperin DC,Littke MH,Leib SR,Leach SE,Hines SA

    更新日期:2007-10-23 00:00:00

  • Biodegradable microspheres as controlled-release tetanus toxoid delivery systems.

    abstract::Purified tetanus toxoid, a high-molecular-weight protein, was entrapped within poly(L-lactic acid) (PLA) and poly(D,L-lactic/glycolic acid) (PLGA) microspheres prepared by either a solvent extraction or a solvent evaporation method carried out in a multiple emulsion system (water-in-oil-in-water). The physical integri...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(94)90092-2

    authors: Alonso MJ,Gupta RK,Min C,Siber GR,Langer R

    更新日期:1994-03-01 00:00:00

  • A canine adenovirus type 2 vaccine vector confers protection against foot-and-mouth disease in guinea pigs.

    abstract::Vaccination is a key element in the control of foot-and-mouth disease (FMD). The majority of the antigenic sites that induce protective immune responses are localized on the FMD virus (FMDV) capsid that is formed by four virus-encoded structural proteins, VP1 to VP4. In the present study, recombinant canine adenovirus...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.02.074

    authors: De Vleeschauwer AR,Zhou X,Lefebvre DJ,Garnier A,Watier F,Pignon C,Lacour SA,Zientara S,Bakkali-Kassimi L,De Clercq K,Klonjkowski B

    更新日期:2018-04-12 00:00:00

  • Antibody induction after combined application of an adjuvanted recombinant FeLV vaccine and a multivalent modified live virus vaccine with a chlamydial component.

    abstract::The compatibility, safety and interaction on antibody induction of a combined vaccine application were assessed. Specific pathogen-free cats were vaccinated with either a modified live virus vaccine containing feline calici- (FCV), herpes- (FHV-1), parvovirus (FPV) and Chlamydophila felis (C. felis), an adjuvanted rec...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.10.030

    authors: Brunner C,Kanellos T,Meli ML,Sutton DJ,Gisler R,Gomes-Keller MA,Hofmann-Lehmann R,Lutz H

    更新日期:2006-03-10 00:00:00

  • Human papillomavirus infection among human immunodeficiency virus-infected women in Maharashtra, India.

    abstract:INTRODUCTION:Frequency and distribution of HPV types in HIV-infected women with and without cervical neoplasia and their determinants have not been widely studied in India. We report and discuss HPV prevalence and type distribution in HIV-infected women. METHODS:HPV genotyping was done using cervical samples from 1109...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.12.060

    authors: Joshi S,Babu JM,Jayalakshmi D,Kulkarni V,Divate U,Muwonge R,Gheit T,Tommasino M,Sankaranarayanan R,Pillai MR

    更新日期:2014-02-19 00:00:00

  • Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

    abstract::In a phase I/II dose escalation study, varying volumes (0.1 ml, 0.5 ml, 1.0 ml and 2.0 ml) of 7-valent pneumococcal conjugate vaccine (PCV) (Prevnar or 0.5 ml of 23-valent pneumococcal polysaccharide vaccine (PPV) were administered to 220 adults 70 through 79 years of age previously vaccinated with 0.5 ml PPV at age 6...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.vaccine.2005.02.017

    authors: Jackson LA,Neuzil KM,Whitney CG,Starkovich P,Dunstan M,Yu O,Nelson JC,Feikin DR,Shay DK,Baggs J,Carste B,Nahm MH,Carlone G

    更新日期:2005-05-25 00:00:00

  • Do parents prefer inactivated or live attenuated influenza vaccine for their children?

    abstract:OBJECTIVES:To determine the proportion of children whose parents prefer them to receive live, attenuated influenza vaccine (LAIV) or inactivated influenza vaccine (IIV), examine reasons for preferences, and determine what percentage of vaccinated children receive other than the preferred type of vaccine and why. METHO...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.10.042

    authors: Santibanez TA,Kahn KE,Bridges CB

    更新日期:2018-11-19 00:00:00

  • Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

    abstract::In this investigation we have generated and defined the immunogenicity of two novel HIV/AIDS vaccine candidates based on the highly attenuated vaccinia virus strains, MVA and NYVAC, efficiently expressing in the same locus (TK) and under the same viral promoter the codon optimized HIV-1 genes encoding gp120 and Gag-Po...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.09.090

    authors: Gómez CE,Nájera JL,Jiménez EP,Jiménez V,Wagner R,Graf M,Frachette MJ,Liljeström P,Pantaleo G,Esteban M

    更新日期:2007-04-12 00:00:00

  • Vaccination with LetiFend® reduces circulating immune complexes in dogs experimentally infected with L. infantum.

    abstract::Domestic dogs constitute the main reservoir of Leishmania infantum and play a key role in transmission to humans. The main tool for controlling infection spread is a safe and effective vaccine, as successful immunization of dogs could significantly reduce the incidence of human visceral leishmaniosis (VL) and is the m...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.10.078

    authors: Cacheiro-Llaguno C,Parody N,Renshaw-Calderón A,Osuna C,Alonso C,Carnés J

    更新日期:2020-01-22 00:00:00

  • Cell culture attenuation eliminates rMd5ΔMeq-induced bursal and thymic atrophy and renders the mutant virus as an effective and safe vaccine against Marek's disease.

    abstract::Marek's disease virus (MDV) encodes a basic leucine zipper oncoprotein, Meq, which structurally resembles jun/fos family of transcriptional activators. It has been clearly demonstrated that deletion of Meq results in loss of transformation and oncogenic capacity of MDV. The rMd5ΔMeq virus provided superior protection ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.05.043

    authors: Lee LF,Heidari M,Zhang H,Lupiani B,Reddy SM,Fadly A

    更新日期:2012-07-20 00:00:00

  • Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial.

    abstract::Estimation of the full disease burden caused by Streptococcus pneumoniae is challenging due to the difficulties in assigning the aetiology especially in lower and upper respiratory infections. We estimated the pneumococcal disease burden by using the vaccine-preventable disease incidence (VPDI) of PHiD-CV10 vaccine (G...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2018.02.088

    authors: Palmu AA,Jokinen J,Nieminen H,Rinta-Kokko H,Ruokokoski E,Puumalainen T,Moreira M,Schuerman L,Borys D,Kilpi TM

    更新日期:2018-03-27 00:00:00

  • A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response.

    abstract::A strategy to improve the immunogenicity of candidate vaccines is to trigger the innate immune system. Triggering of CD40 at the surface of dendritic cells (DC) is essential in the induction of an efficient immune response. Although CD40 agonist antibodies have been shown to be potent inducers of immune responses in e...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.05.028

    authors: Miconnet I,Pantaleo G

    更新日期:2008-07-29 00:00:00

  • Changes in serotype distribution of Haemophilus influenzae meningitis isolates identified through laboratory-based surveillance following routine childhood vaccination against H. influenzae type b in Brazil.

    abstract::Following routine childhood vaccination against Haemophilus influenzae type b (Hib) disease in Brazil in 1999, passive laboratory surveillance reported increasing numbers of non-b serotypes and nontypeable H. influenzae (NTHi) from meningitis cases. To characterize this increase, we analyzed data on 3910 H. influenzae...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.09.053

    authors: Zanella RC,Bokermann S,Andrade AL,Flannery B,Brandileone MC

    更新日期:2011-11-08 00:00:00